Clinical Trials on T-Cell Lymphoma in Hong Kong

Total 699 results

National Cancer Institute (NCI)

Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

Down Syndrome | B Acute Lymphoblastic Leukemia | B Lymphoblastic Lymphoma

United States, Canada, Puerto Rico, Australia, New Zealand
Pfizer

Completed

Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

Carcinoma, Non-small Cell

United States, Taiwan, Korea, Republic of, Japan, Hong Kong
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission

Childhood Acute Lymphoblastic Leukemia in Remission

United States, Canada, Australia
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI); Aventis Pharmaceuticals

Terminated

Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Israel
Amgen

Recruiting

Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

Small Cell Lung Carcinoma

United States, Spain, Austria, Switzerland, United Kingdom, France, Australia, Germany, Japan, Taiwan, Poland, Hong Kong, Netherlands
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd; Seagen Inc.

Terminated

A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, (CheckMate 812)

Hodgkin's Disease

United States, Japan, Puerto Rico
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Neurobehavioral Complications in Children Who Were Previously Treated With Steroids and Intrathecal Therapy for Acute Lymphoblastic Leukemia

Leukemia | Neurotoxicity | Long-term Effects Secondary to Cancer Therapy in Children | Psychosocial Effects of Cancer and Its Treatment

United States
National Cancer Institute (NCI)

Active, not recruiting

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia

United States, Canada, Puerto Rico, Australia, New Zealand
AVEO Pharmaceuticals, Inc.
Biodesix, Inc.

Terminated

A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label (FOCAL)

Non-small Cell Lung Cancer

Korea, Republic of, United States, Australia, Taiwan, Singapore, Hong Kong, Italy
Nordic Nanovector
ICON Clinical Research

Active, not recruiting

A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01)

Follicular Lymphoma | Non-Hodgkin Lymphoma

United States, Korea, Republic of, Australia, Austria, Belgium, Canada, Croatia, Czechia, Denmark, Finland, France, Hungary, Ireland, Israel, Italy, Netherlands, Norway, Poland, Singapore, Spain, Sweden, Switzerland, Turkey, United Kingdom
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Childhood B Acute Lymphoblastic Leukemia

United States, Canada, Australia, New Zealand, Switzerland
Acerta Pharma BV

Active, not recruiting

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Chronic Lymphocytic Leukemia

Austria, Italy, Spain, United Kingdom, Belgium, Taiwan, France, Korea, Republic of, Hungary, United States, Ukraine, Canada, Australia, Germany, Israel, Czechia, Russian Federation, Slovakia, Poland, Bulgaria, New Zealand, Sweden, C... and more
Pfizer

Completed

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Non-small Cell Lung Cancer

United States, Taiwan, Korea, Republic of, Australia, Brazil, Spain, United Kingdom, Singapore, Canada, Hong Kong, Poland, Puerto Rico
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Ann Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent... and other conditions

United States, Puerto Rico
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.

Non-Small Cell Lung Cancer

Australia, Belgium, France, Italy, Hong Kong, Canada, Denmark, Taiwan, Russian Federation, United Kingdom, Spain, Hungary, Czech Republic, Poland, Germany, Netherlands
Hoffmann-La Roche

Recruiting

A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (SKYSCRAPER-15)

Non-small Cell Lung Cancer (NSCLC)

Korea, Republic of, United States, China, Japan, Australia, Taiwan, Brazil, Argentina, Hong Kong
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)

Lung Cancer | Non Small Cell Lung Cancer | Squamous Non Small Cell Lung Cancer | Nonsquamous Non Small Cell Lung Cancer

United States, Taiwan, Korea, Republic of, Australia, Singapore, Hong Kong, Canada
BioAtla, Inc.

Recruiting

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

Non-Small-Cell Lung Cancer

United States, Hong Kong, Taiwan, Spain, Greece, Germany, Italy, Poland
Hoffmann-La Roche

Completed

Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

Non-small Cell Lung Cancer

Belgium, Italy, Portugal, Spain, Germany, Turkey, France, Hong Kong, Korea, Republic of, Poland, Russian Federation, Hungary, Norway, Bulgaria, Slovakia
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Untreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic Leukemia

United States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
Novartis Pharmaceuticals

Terminated

Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy (A+B)

Lymphoma, Follicular

United States, Belgium, Italy, Hong Kong, Austria, Germany, Japan, Russian Federation, United Kingdom, Canada, Slovakia, Poland, Ukraine, Puerto Rico, Greece, France, Argentina
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Leukemia

United States, Canada, Puerto Rico, Australia, Netherlands, New Zealand, Switzerland
Merck KGaA, Darmstadt, Germany

Completed

Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX) (FLEX)

Non Small Cell Lung Cancer (NSCLC)

Sweden, Australia, Brazil, Bulgaria, Czech Republic, France, Italy, Korea, Republic of, Mexico, Russian Federation, Spain, Turkey, United Kingdom, Germany, Poland, Ukraine, Argentina, Austria, Hungary, Netherlands, Slovakia, Taiwan, Chil... and more
Hoffmann-La Roche

Completed

A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

Anemia

Belgium, Italy, Poland, Spain, Hong Kong, Canada, France, Greece, Czech Republic, Austria, Estonia, Hungary, Australia, Germany, Finland
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Collecting and Storing Tissue From Young Patients With Cancer

Soft Tissue Sarcoma | Lymphoma | Acute Myeloid Leukemia | Leukemia | Osteosarcoma | Acute Lymphoblastic Leukemia | Ewing Sarcoma | Rhabdoid Tumor | Neuroblastoma | Retinoblastoma | Rhabdomyosarcoma | Malignant Neoplasm | Germ Cell Tumor | Central Nervous System Neoplasm

United States, Canada
Translational Oncology Research International

Completed

Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer

United States
AstraZeneca

Recruiting

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) (TARGET)

Stage II-IIIB Non-small Cell Lung Carcinoma

Spain, Korea, Republic of, Philippines, Italy, United States, Malaysia, Taiwan, Thailand, Hong Kong, United Kingdom, Singapore
Bristol-Myers Squibb

Completed

Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma

Melanoma

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

Chronic Lymphocytic Leukemia | Small Lymphocytic Leukemia

Poland, Turkey, Denmark, Singapore, Hungary, Hong Kong, Taiwan, Chile, Malaysia, Brazil, Guatemala, China, South Africa, Colombia, United States, Ukraine, Australia, Mexico, Romania
Novartis Pharmaceuticals

No longer available

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

Non-small Cell Lung Cancer (NSCLC)

United States, Argentina, Korea, Republic of, Hong Kong, Thailand, Mexico, Jordan, Colombia, India, Philippines
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia

United States, Canada, Australia, Switzerland
Bayer

Completed

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

Lymphoma, Non-Hodgkin

Belgium, France, Spain, Hong Kong, Turkey, Russian Federation, Singapore, United States, Canada, Germany, Australia, New Zealand, Finland, Austria, United Kingdom, Bulgaria, Hungary, Italy, Israel, Korea, Republic of, Poland, Port... and more
Southwest Oncology Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group

Completed

SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant

Lymphoma | Multiple Myeloma and Plasma Cell Neoplasm

United States
AstraZeneca

Completed

First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia (IPASS)

Non-Small Cell Lung Cancer

Philippines, China, Malaysia, Japan, Hong Kong, Taiwan, Thailand, Indonesia, Singapore
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia...

Completed

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States
Gilead Sciences

Active, not recruiting

Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma (ELEVATE HNSCC)

Head and Neck Squamous Cell Carcinoma

United States, France, Spain, Australia, Italy, Belgium, Hong Kong, Portugal, Poland, United Kingdom, Germany
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Leukemia | Solid Tumor | Hematopoietic Cell Transplantation Recipient

United States, Puerto Rico
Pfizer
Bristol-Myers Squibb

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Multiple Myeloma

United States, Canada
Xcovery Holdings, Inc.

Active, not recruiting

eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Non-small Cell Lung Cancer

Spain, United States, China, Korea, Republic of, Hong Kong, United Kingdom, Poland, Israel, Germany, France, Argentina, Australia, Brazil, Canada, Czechia, Italy, Netherlands, Russian Federation, Turkey, Belgium
Eisai Inc.

Completed

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Hong Kong, Taiwan, Korea, Republic of, Singapore, Thailand, Malaysia
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy (CheckMate722)

Non-Small-Cell Lung Carcinoma

United States, China, Taiwan, Spain, Korea, Republic of, France, Canada, Hong Kong, Japan, Singapore
National Cancer Institute (NCI)
Radiation Therapy Oncology Group

Completed

Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer

Stage IA Uterine Corpus Cancer AJCC v7 | Stage IB Uterine Corpus Cancer AJCC v7 | Stage II Uterine Corpus Cancer AJCC v7 | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus... and other conditions

United States, Canada, Hong Kong
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)

Squamous Cell Carcinoma of the Head and Neck

Brazil, Italy, United Kingdom, United States, Hong Kong, France, Netherlands, Germany, Argentina, Canada, Japan, Korea, Republic of, Spain, Switzerland, Taiwan
Forma Therapeutics, Inc.
Medpace, Inc.

Completed

A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients

Healthy Volunteers | Sickle Cell Disease

United States
National Cancer Institute (NCI)

Recruiting

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
Pharmacyclics LLC.

Terminated

Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer

Non-Small Cell Lung Carcinoma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

Lymphoma

United States

Clinical Trials on T-Cell Lymphoma in Hong Kong

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations